it is true sir @krnel. I also have a lot of Cannabis Plant.

Cannabis-based treatment experiments have been successfully used in the care of children with severe and rare epilepsy. The clinical trial was the first of four levels of a marijuana treatment test that began last year.

GW Pharmaceutical drug producers hope to prove the benefits of cannabinoids, the active ingredients that are in cannabis. In his statement, the pharmaceutical company claims that there are 120 epilepsy patients tested taking Epidiolex drugs.

From the trial it was found that patients experienced an average decrease in seizure intensity by 39 percent in one month. It is far greater than the use of placebo drugs.

This trial is intended to treat people with Dravet syndrome, a condition that is more difficult to handle than patients with epilepsy. Dravet itself is usually shown with behavioral problems, cognitive impairment, ataxia (state of unrest) as well as prolonged seizures.

"This demonstrates that cannabinoids can produce and clinically provide information while offering promising new classes of treatment," said Julian Gover, Chief Executive of GW Pharmaceutical, as quoted by the Independent.

Gover said it is currently awaiting a meeting with the US Food and Drug Administration, to get approval for the treatment of epilepsy patients with this drug-based drug.

Executive Director of the Dravet Syndrome Foundation, Marry Anne Meskis, said that Dravet's syndrome is one of the disasters that can be triggered by epilepsy in children. To handle this, safe and effective care is required.

"We are very pleased to take many lessons from these results and bring hope to children and families alike, who have been living with seizure problems," he said.

GW Pharmaceutical was established in 1998 and concentrates on the development of therapeutic drugs using cannabis. The London-based pharmaceutical company has an official license to grow marijuana for use as a drug in the south of England.